Back to Search
Start Over
The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma
- Source :
- Current oncology reports. 18(11)
- Publication Year :
- 2016
-
Abstract
- Sequential targeted therapies are the standard of care for patients with metastatic renal cell carcinoma (mRCC). Several drugs are available for patients whose disease progresses while they receive initial tyrosine kinase inhibitor (TKI) therapy; these include nivolumab (an inhibitor of PD-1 receptor), everolimus (an inhibitor of the mechanistic target of rapamycin) or additional TKIs. Until now, there has been no clinical evidence to support the use of one strategy versus another, so investigators and physicians rely on experience, judgement and findings from molecular analyses to select the appropriate treatment. However, with the arrival of nivolumab and cabozantinib that provide an overall survival higher than other alternative treatments, therapeutic strategies may have changed. Here, we discuss findings from preclinical and clinical studies that might help clinicians to choose the optimal treatment approach for patients with mRCC who progress to initial therapy.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Cabozantinib
medicine.drug_class
medicine.medical_treatment
Antineoplastic Agents
Disease
Pharmacology
Tyrosine-kinase inhibitor
Targeted therapy
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Renal cell carcinoma
Internal medicine
medicine
Humans
Mechanistic target of rapamycin
Carcinoma, Renal Cell
Everolimus
biology
business.industry
medicine.disease
Kidney Neoplasms
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
biology.protein
Nivolumab
business
medicine.drug
Subjects
Details
- ISSN :
- 15346269
- Volume :
- 18
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Current oncology reports
- Accession number :
- edsair.doi.dedup.....9bc44a68a0452bc409c78074a2ed8bb0